Aimmune Therapeutics Inc. (NASDAQ:AIMT) posted its earnings results on Monday. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by $0.08.

Shares of Aimmune Therapeutics (NASDAQ:AIMT) opened at 26.70 on Tuesday. The firm’s market capitalization is $1.13 billion. The stock has a 50 day moving average of $17.56 and a 200-day moving average of $14.49. Aimmune Therapeutics has a 1-year low of $9.77 and a 1-year high of $27.31.

A number of analysts have recently issued reports on AIMT shares. Zacks Investment Research cut shares of Aimmune Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 19th. Wedbush reaffirmed an “outperform” rating and set a $42.00 price target on shares of Aimmune Therapeutics in a research report on Wednesday, August 10th. Credit Suisse Group AG reaffirmed a “buy” rating and set a $35.00 price target on shares of Aimmune Therapeutics in a research report on Friday, August 19th. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $38.00 price target on shares of Aimmune Therapeutics in a research report on Friday, September 23rd. Finally, JMP Securities initiated coverage on shares of Aimmune Therapeutics in a research report on Monday, September 26th. They set an “outperform” rating and a $30.00 price target on the stock. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $32.20.

In related news, insider Mary M. Rozenman sold 30,000 shares of the firm’s stock in a transaction on Thursday, September 8th. The stock was sold at an average price of $16.80, for a total value of $504,000.00. Following the completion of the sale, the insider now owns 30,000 shares of the company’s stock, valued at $504,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Mary M. Rozenman sold 24,096 shares of the firm’s stock in a transaction on Friday, November 4th. The stock was sold at an average price of $17.60, for a total value of $424,089.60. Following the completion of the sale, the insider now directly owns 24,096 shares of the company’s stock, valued at approximately $424,089.60. The disclosure for this sale can be found here. Company insiders own 24.56% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the company. Parametric Portfolio Associates LLC raised its stake in shares of Aimmune Therapeutics by 23.4% in the second quarter. Parametric Portfolio Associates LLC now owns 48,270 shares of the company’s stock worth $522,000 after buying an additional 9,156 shares during the last quarter. Citadel Advisors LLC purchased a new position in shares of Aimmune Therapeutics during the second quarter valued at approximately $186,000. State Street Corp raised its position in shares of Aimmune Therapeutics by 123.6% in the second quarter. State Street Corp now owns 354,062 shares of the company’s stock valued at $3,831,000 after buying an additional 195,718 shares in the last quarter. Pictet Asset Management Ltd. raised its position in shares of Aimmune Therapeutics by 798.5% in the second quarter. Pictet Asset Management Ltd. now owns 831,093 shares of the company’s stock valued at $12,757,000 after buying an additional 738,593 shares in the last quarter. Finally, Rhumbline Advisers raised its position in shares of Aimmune Therapeutics by 98.5% in the second quarter. Rhumbline Advisers now owns 21,200 shares of the company’s stock valued at $229,000 after buying an additional 10,520 shares in the last quarter. 70.49% of the stock is owned by institutional investors.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc, formerly Allergen Research Corporation, is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

5 Day Chart for NASDAQ:AIMT

Receive News & Stock Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related stocks with our FREE daily email newsletter.